In the beginning of November, worldwide leaders in the treatment of Alzheimer’s disease and sites’ clinical trial teams shared the results, methodologies, therapeutic options, and challenges that were brought to the industry recently. This year CTAD dialogues revolved among important topic of the necessity to understand how we can predict the risk of AD progression. The participants presented results of their preclinical research, Phase II and Phase III multinational trials.
Having participated as Principal Investigator in over a 100 trials in Alzheimer’s Disease, Jeffrey was a welcome guest at this meeting. Dr. Apter, his colleagues and fellow researchers discussed innovative solutions, study design issues, promising current developments and future trends of clinical trials, — including clinical trials conducted in the Eastern Europe, Russia and India.